

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

TOV-21G

RRID:CVCL_3613

Type: Cell Line

Proper Citation

RRID:CVCL_3613

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3613

Proper Citation: RRID:CVCL_3613

Description: Cell line TOV-21G is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian clear cell adenocarcinoma

Defining Citation: [PMID:10949993](#), [PMID:11641787](#), [PMID:19058220](#), [PMID:20081105](#), [PMID:20204287](#), [PMID:22460905](#), [PMID:22705003](#), [PMID:22710073](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:24224046](#), [PMID:25230021](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26388441](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TOV-21G

Synonyms: TOV-21g, TOV21G, TOV21

Cross References: BTO:BTO_0005183, CLO:CLO_0009385, EFO:EFO_0022427, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-3577, ATCC:CRL-

11730, BCRC:60407, BCRJ:0236, BioGRID_ORCS_Cell_line:446, BioSample:SAMN02800401, BioSample:SAMN03471875, BioSample:SAMN10988233, cancercellines:CVCL_3613, CancerTools:161764, Cell_Model_Passport:SIDM01169, ChEMBL-Cells:ChEMBL4630710, ChEMBL-Targets:ChEMBL4630716, Cosmic:1066220, Cosmic:1102820, Cosmic:1139221, Cosmic:1223320, Cosmic:1305319, Cosmic:1312195, Cosmic:1328069, Cosmic:1434896, Cosmic:1449932, Cosmic:1707558, Cosmic:1708383, Cosmic:2074249, Cosmic-CLP:1240222, DepMap:ACH-000885, EGA:EGAS00001000978, GDSC:1240222, GEO:GSM289385, GEO:GSM289386, GEO:GSM289416, GEO:GSM289417, GEO:GSM313692, GEO:GSM416684, GEO:GSM659408, GEO:GSM784567, GEO:GSM851945, GEO:GSM887711, GEO:GSM888804, GEO:GSM1176285, GEO:GSM1291153, GEO:GSM1374965, GEO:GSM1670547, GEO:GSM2475008, IARC_TP53:21094, LiGeA:CCLE_476, LINCS_LDP:LCL-1530, PharmacDB:TOV21G_1605_2019, PRIDE:PXD000901, PRIDE:PXD030304, Progenetix:CVCL_3613, PubChem_Cell_line:CVCL_3613, Wikidata:Q54972808

ID: CVCL_3613

Record Creation Time: 20220427T221632+0000

Record Last Update: 20260905T182559+0000

Ratings and Alerts

No rating or validation information has been found for TOV-21G.

Warning: Discontinued: BCRJ; 0236

Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Chen Y, et al. (2026) The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression. Oncogene, 45(27), 2714.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. *Cell reports*, 45(4), 117198.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. *Cancer research*, 86(11), 2623.

Hayashi M, et al. (2025) Prognostic Significance of S100A4 in Ovarian Clear Cell Carcinoma: Its Relation to Tumor Progression and Chemoresistance. *Cancers*, 17(2).

Simões-Sousa S, et al. (2025) ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. *Cell reports*, 44(9), 116277.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. *Cell chemical biology*, 32(4), 556.

Kawahara N, et al. (2025) Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1 β positive clear cell carcinoma. *Cell death & disease*, 16(1), 879.

Nair JR, et al. (2024) Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. *iScience*, 27(12), 111283.

Ferrari AJ, et al. (2023) H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. *JCI insight*, 8(12).

Okano F, et al. (2023) Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. *Cancer research communications*, 3(4), 640.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Handley KF, et al. (2023) Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. *Gynecologic oncology*, 173, 114.

Nakagawa M, et al. (2023) Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma. *Molecular oncology*, 17(10), 2168.

Yu ZC, et al. (2023) Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors. *Cancer research*, 83(16), 2750.

Dorrigiv D, et al. (2023) Pixelated Microfluidics for Drug Screening on Tumour Spheroids and Ex Vivo Microdissected Tumour Explants. *Cancers*, 15(4).

Parente-Pereira AC, et al. (2022) Generation and application of TGF β -educated human V α 9V β 2 T cells. *STAR protocols*, 3(2), 101319.